Standout Papers

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, ... 2021 2026 2022 2024385
  1. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021)
    Paul M. Ridker, Matt Devalaraja et al. The Lancet

Citation Impact

10 from Science/Nature 69 standout
Sub-graph 1 of 21

Citing Papers

Adipokines: masterminds of metabolic inflammation
2024 Standout
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
2024 Standout
1 intermediate paper

Works of Larry Lo being referenced

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
2021 Standout
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
2020

Author Peers

Author Surgery Molecular Biology Hematology Immunology Epidemiology Last Decade Papers Cites
Larry Lo 168 552 111 413 185 18 1.2k
Lyudmila V. Yanshole 4 349 16 29 32 569
S. C. Flood 2 7 337
Steffen Nestler 1 5 16 347
Kalevi Visuri 30 387 16 4 16 571
Shuh Shing Lee 6 1 30 261

All Works

Loading papers...

Rankless by CCL
2026